Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
$SUPN
Sector
Primary listing
Employees
674
Headquarters
Website
SUPN Metrics
BasicAdvanced
$2.5B
39.16
$1.14
0.74
-
Price and volume
Market cap
$2.5B
Beta
0.74
52-week high
$46.79
52-week low
$29.16
Average daily volume
862K
Financial strength
Current ratio
2.58
Quick ratio
2.317
Long term debt to equity
2.292
Total debt to equity
2.987
Profitability
EBITDA (TTM)
132.223
Gross margin (TTM)
88.53%
Net profit margin (TTM)
9.70%
Operating margin (TTM)
7.75%
Effective tax rate (TTM)
21.50%
Revenue per employee (TTM)
$990,000
Management effectiveness
Return on assets (TTM)
2.39%
Return on equity (TTM)
6.38%
Valuation
Price to earnings (TTM)
39.163
Price to revenue (TTM)
3.747
Price to book
2.36
Price to tangible book (TTM)
5.4
Price to free cash flow (TTM)
13.408
Free cash flow yield (TTM)
7.46%
Free cash flow per share (TTM)
3.341
Growth
Revenue change (TTM)
5.55%
Earnings per share change (TTM)
1,411.53%
3-year revenue growth (CAGR)
1.82%
10-year revenue growth (CAGR)
18.84%
3-year earnings per share growth (CAGR)
3.82%
10-year earnings per share growth (CAGR)
27.22%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
Bulls say / Bears say
Acquiring Sage Therapeutics for up to $795 million brings ZURZUVAE®, the first FDA-approved oral therapy for postpartum depression, expanding Supernus's portfolio—with the transaction expected to add to earnings from 2026 and deliver up to $200 million in annual cost synergies.
The FDA approval of Onapgo™, a new apomorphine infusion device for Parkinson’s disease ‘off episodes,’ addresses a significant unmet need and is forecasted to reach U.S. peak sales of $200–300 million, strengthening Supernus’s growth outlook.
A persistent shortage of ADHD drugs over the past two years has restricted supply of existing stimulants and increased demand for branded treatments like Qelbree, supporting its growing market share and sales.
The Sage acquisition includes up to $3.50 per share in contingent milestone payments tied to ZURZUVAE’s net sales and Japanese regulatory approval, which may create additional future cash obligations for Supernus and comes with uncertainty about whether these milestones will be achieved.
Onapgo’s FDA approval followed previous rejections in 2022 and 2024, highlighting the risk of execution and the potential for further regulatory setbacks for future pipeline products.
ZURZUVAE earned only $13.8 million in U.S. net sales in Q1 2025, of which Supernus will report just half as collaboration income, suggesting the immediate financial impact to the top line may be limited.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
SUPN News
AllArticlesVideos
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire2 months ago
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $2.5B as of September 18, 2025.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 39.16 as of September 18, 2025.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.